IL217857A - Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone) - Google Patents
Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone)Info
- Publication number
- IL217857A IL217857A IL217857A IL21785712A IL217857A IL 217857 A IL217857 A IL 217857A IL 217857 A IL217857 A IL 217857A IL 21785712 A IL21785712 A IL 21785712A IL 217857 A IL217857 A IL 217857A
- Authority
- IL
- Israel
- Prior art keywords
- ganaxolone
- 3alpha
- 5alpha
- pregnan
- 3beta
- Prior art date
Links
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 title 2
- 229950006567 ganaxolone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23355309P | 2009-08-13 | 2009-08-13 | |
| PCT/US2010/045176 WO2011019821A2 (en) | 2009-08-13 | 2010-08-11 | METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL217857A0 IL217857A0 (en) | 2012-03-29 |
| IL217857A true IL217857A (en) | 2016-03-31 |
Family
ID=43586809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL217857A IL217857A (en) | 2009-08-13 | 2012-01-31 | Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8362286B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2464653B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5745517B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101778603B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102549007B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010282570B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012003085B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2769820C (cg-RX-API-DMAC7.html) |
| EA (1) | EA024269B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2524724T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL217857A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012001728A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ597940A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011019821A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017290B1 (ru) | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
| US9629853B2 (en) | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| CZ305837B6 (cs) * | 2015-02-25 | 2016-03-30 | Vysoká škola chemicko - technologická v Praze | (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina |
| US10780099B2 (en) * | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| CN106279326A (zh) * | 2016-08-09 | 2017-01-04 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法 |
| CN106366149B (zh) * | 2016-08-09 | 2018-01-23 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法 |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| IT201800009683A1 (it) * | 2018-10-22 | 2020-04-22 | Ind Chimica Srl | Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone) |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
| IL293525A (en) | 2019-12-06 | 2022-08-01 | Marinus Pharmaceuticals Inc | Ganaxolone for use in the treatment of multiple sclerosis complex |
| IT202000021316A1 (it) | 2020-09-09 | 2022-03-09 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) * | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| JP4008024B2 (ja) * | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| FR2720747B1 (fr) * | 1994-06-02 | 1996-07-12 | Roussel Uclaf | Nouveau procédé de préparation d'un stéroïde 16béta-méthyl et nouveaux intermédiaires. |
| PT808325E (pt) * | 1994-11-23 | 2001-06-29 | Cocensys Inc | Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba |
| WO2006010085A1 (en) * | 2004-07-09 | 2006-01-26 | Roxro Pharma, Inc. | Use of neurosteroids to treat neuropathic pain |
| EA017290B1 (ru) * | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
-
2010
- 2010-08-11 CA CA2769820A patent/CA2769820C/en active Active
- 2010-08-11 ES ES10808696.8T patent/ES2524724T3/es active Active
- 2010-08-11 KR KR1020127006429A patent/KR101778603B1/ko active Active
- 2010-08-11 US US12/854,226 patent/US8362286B2/en active Active
- 2010-08-11 EP EP10808696.8A patent/EP2464653B1/en active Active
- 2010-08-11 NZ NZ597940A patent/NZ597940A/xx unknown
- 2010-08-11 MX MX2012001728A patent/MX2012001728A/es active IP Right Grant
- 2010-08-11 JP JP2012524841A patent/JP5745517B2/ja active Active
- 2010-08-11 WO PCT/US2010/045176 patent/WO2011019821A2/en not_active Ceased
- 2010-08-11 BR BR112012003085-0A patent/BR112012003085B1/pt active IP Right Grant
- 2010-08-11 AU AU2010282570A patent/AU2010282570B2/en active Active
- 2010-08-11 CN CN201080035660.3A patent/CN102549007B/zh active Active
- 2010-08-11 EA EA201270241A patent/EA024269B1/ru active IP Right Revival
-
2012
- 2012-01-31 IL IL217857A patent/IL217857A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN102549007B (zh) | 2015-03-18 |
| EA201270241A1 (ru) | 2013-09-30 |
| EP2464653A2 (en) | 2012-06-20 |
| EP2464653B1 (en) | 2014-10-22 |
| ES2524724T3 (es) | 2014-12-11 |
| JP2013501803A (ja) | 2013-01-17 |
| EA024269B1 (ru) | 2016-09-30 |
| CA2769820C (en) | 2017-06-27 |
| US20110040112A1 (en) | 2011-02-17 |
| IL217857A0 (en) | 2012-03-29 |
| KR20120084715A (ko) | 2012-07-30 |
| WO2011019821A3 (en) | 2011-06-16 |
| KR101778603B1 (ko) | 2017-09-14 |
| JP5745517B2 (ja) | 2015-07-08 |
| MX2012001728A (es) | 2012-06-01 |
| AU2010282570B2 (en) | 2014-04-24 |
| CA2769820A1 (en) | 2011-02-17 |
| HK1171761A1 (en) | 2013-04-05 |
| BR112012003085A2 (pt) | 2020-12-01 |
| AU2010282570A1 (en) | 2012-02-23 |
| US8362286B2 (en) | 2013-01-29 |
| BR112012003085B1 (pt) | 2021-06-01 |
| CN102549007A (zh) | 2012-07-04 |
| WO2011019821A2 (en) | 2011-02-17 |
| NZ597940A (en) | 2013-03-28 |
| EP2464653A4 (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217857A (en) | Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone) | |
| GB0905140D0 (en) | Method | |
| GB0911905D0 (en) | Method | |
| GB0902476D0 (en) | Method | |
| GB0910707D0 (en) | Method | |
| GB0913525D0 (en) | Method | |
| GB0918940D0 (en) | Method | |
| GB0913433D0 (en) | Method | |
| GB0901444D0 (en) | Method | |
| GB0921375D0 (en) | Method | |
| GB0917457D0 (en) | Method | |
| GB0916570D0 (en) | Method | |
| GB0905367D0 (en) | Method | |
| GB0903316D0 (en) | Method | |
| GB0916013D0 (en) | Method | |
| GB0908770D0 (en) | Method | |
| ZA201203155B (en) | Method for isolating methylglycinenitrile-n,n-diacetonitrile | |
| GB0902034D0 (en) | Method | |
| PL2319671T3 (pl) | Sposób wytwarzania płyt OSB | |
| GB0920596D0 (en) | Method | |
| GB0919901D0 (en) | Method | |
| GB0917988D0 (en) | Method | |
| GB0911362D0 (en) | Method | |
| GB0904946D0 (en) | Method | |
| GB0900560D0 (en) | Method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |